The effects of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 on the secretory capacity of human blood eosinophils.
The effects of recombinant human GM-CSF and interleukin-3 (IL-3) on human blood eosinophil survival, activation, and secretion were studied. Purified normal density eosinophils from patients with the idiopathic hypereosinophilic syndrome (HES) survived in culture for 7 days (50% viable) in the presence of 50 nM GM-CSF or 50 nM IL-3. Neutrophils did not survive after 4 days. No eosinophils survived in the absence of GM-CSF or IL-3. In two out of five patients studied, the cultured eosinophils became elongated with numerous processes. In all five patients the cells became adherent, but there were no morphological signs of degranulation. Both GM-CSF and IL-3 activated eosinophils, transforming the storage form of eosinophil cationic protein (ECP) into the secreted form. The proportion of activated cells increased from less than 20% to over 50% after 4 days in culture. However, GM-CSF and IL-3 did not induce secretion on their own. On the other hand, when GM-CSF/IL-3-activated eosinophils were exposed to known secretory stimuli, there was a six-fold increase in the amount of ECP released when the cells were stimulated with sepharose coated with C3b, and a two-fold increase when they were stimulated with sepharose-activated whole autologous serum. Eosinophils from patients taking steroids were unable to secrete their granule contents, even though they became activated by GM-CSF and IL-3. A novel finding was that sepharose-activated whole serum was an extremely potent secretory signal for ECP, releasing up to 50% of the total ECP content. These studies showed that GM-CSF and IL-3 prime eosinophil effector function by initiating granule solubilization which is the first step in the secretory event, without affecting the subsequent extracellular release of granule proteins.
Department of Cellular & Molecular Sciences, St George's Hospital Medical School, London, England.
P C
PC
Tai
C J
CJ
Spry
D001798:Blood Proteins / Q000378:metabolism; D002470:Cell Survival; D002478:Cells, Cultured; D003115:Colony-Stimulating Factors / Q000276:immunology* / Q000494:pharmacology; D047091:Eosinophil Granule Proteins; D004802:Eosinophilia / Q000097:blood*; D004804:Eosinophils / Q000276:immunology / Q000378:metabolism*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000276:immunology* / Q000494:pharmacology; D006801:Humans; D007124:Immunoenzyme Techniques; D066298:In Vitro Techniques; D007377:Interleukin-3 / Q000276:immunology* / Q000494:pharmacology; D011994:Recombinant Proteins / Q000276:immunology; D012260:Ribonucleases
D001798:Blood Proteins; D003115:Colony-Stimulating Factors; D047091:Eosinophil Granule Proteins; D006133:Growth Substances; D007377:Interleukin-3; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D012260:Ribonucleases